GPH 201 - LENZ Therapeutics
Alternative Names: GPH-201 - LENZ TherapeuticsLatest Information Update: 26 Mar 2024
At a glance
- Originator Graphite Bio
- Developer LENZ Therapeutics
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Severe combined immunodeficiency
Most Recent Events
- 21 Mar 2024 LENZ Therapeutics has merged with Graphite Bio to form LENZ Therapeutics
- 21 Mar 2022 GPH 201 - Graphite Bio is available for licensing as of 21 Mar 2022. https://graphitebio.com/ 9352654
- 01 Mar 2021 Preclinical trials in Severe-combined-immunodeficiency in USA (Parenteral) before March 2021 (Graphite Bio pipeline, March 2021)